Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price Target & Predictions
ZYNE Stock Forecast
Zynerba Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ZYNE Analyst Ratings
According to 1 Wall Street analysts, Zynerba Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ZYNE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 23, 2022 | Canaccord Genuity | Buy | Buy | Hold |
Zynerba Pharmaceuticals's last stock rating was published by Canaccord Genuity on Jun 23, 2022. The company gave ZYNE a "Buy" rating, the same as its previous rate.
Zynerba Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FLGC | Flora Growth | $0.97 | $173.50 | 17786.60% | Hold |
| ZYNE | Zynerba Pharmaceuticals | $1.30 | $11.00 | 746.15% | Buy |
| EBS | Emergent BioSolutions | $7.87 | $51.50 | 554.38% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| CLVR | Clever Leaves | - | $4.30 | - | Buy |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
ZYNE Forecast FAQ
Is Zynerba Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Zynerba Pharmaceuticals (ZYNE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ZYNE's total ratings.